Month: June 2024

London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275. “This U.S. patent goes to the heart of Vidac’s efforts to develop an entirely new class of cancer drugs for patients. Our molecules have the ability to dislodge the HK2 enzyme from the mitochondrial VDAC pores, which reverses...

Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announces that the first patient has been enrolled in the Phase II part of the randomized Phase I/II clinical trial of the individualized therapeutic cancer vaccine, TG4050, in the adjuvant treatment of head and neck cancer. Patient screening and enrollment are active, with the aim of enrolling 80 patients internationally in the overall Phase I/II trial. TG4050 is based on Transgene’s myvac® viral vector platform and NEC’s...

   Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan PARIS, FRANCE, 3 June 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 400,000, or about 0.47% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan and its new employee share-ownership plan. This program is made pursuant to the authorization granted by the Company’s Annual General Meeting, held on 28 May 2024. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience....

BW Energy: Appraisal confirms material Hibiscus field reserve increase Reference is made to the stock exchange notice by BW Energy on 20 May 2024 announcing a substantial oil discovery on the northern flank of the Hibiscus field. BW Energy has now concluded the drilling and the logging of the DHIBM-7P pilot well, confirming a substantial oil discovery with good reservoir quality and a material uplift to the Hibiscus area. The Company’s preliminary evaluation indicates an increase in Hibiscus gross recoverable reserves (mid-case) of approximately 8 million barrels of oil to 12 million barrels of oil. The Company plans to complete the well as a development well later in 2024. The DHIBM-7P pilot was drilled from the MaBoMo production platform to a total depth of 3,941 metres. The target area is located approximately 1.5 kilometres north-northwest...

GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company’s American depositary shares (the...

— Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities — — New AMD Instinct MI325X accelerator expected to be available in Q4 2024 with up to 288GB of HBM3E memory; new AMD Instinct MI350 series accelerators based on AMD CDNA 4 architecture expected to be available in 2025 with 35x generational increase in AI inference performance — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — At Computex 2024, AMD (NASDAQ: AMD) showcased the growing momentum of the AMD Instinct™ accelerator family during the opening keynote by Chair and CEO Dr. Lisa Su. AMD unveiled a multiyear, expanded AMD Instinct accelerator roadmap which will bring an annual cadence of leadership AI performance and memory capabilities at every generation. The updated roadmap starts with the new AMD...

Ryzen AI 300 SeriesAMD Ryzen AI 300 Series Processor— AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs — — AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content Creation — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — Today, during Computex 2024, AMD (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new AMD Ryzen™ AI 300 Series processors with the world’s most powerful Neural Processing Unit (NPU)1 for next-gen AI PCs that pave the way for a future full of AI-infused computing directly on your laptop. AMD is also introducing next-gen AMD Ryzen™ 9000 Series processors for desktops, further solidifying...

— Expanded AMD Instinct accelerator roadmap brings annual cadence of leadership AI accelerators; next generation AMD EPYC processors to extend data center CPU leadership — — New AMD Ryzen AI 300 Series laptop and AMD Ryzen 9000 Series desktop processors deliver leading performance for Copilot+ PCs, gaming, content creation and productivity — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — Today at the Computex 2024 opening keynote, AMD (NASDAQ: AMD) detailed new leadership CPU, NPU and GPU architectures powering end-to-end AI infrastructure from the data center to PCs. AMD unveiled an expanded AMD Instinct™ accelerator roadmap, introducing an annual cadence of leadership AI accelerators including the new AMD Instinct MI325X accelerator with industry-leading memory capacity planned to be available in Q4 2024. AMD also previewed...

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy Under the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDA Immutep retains commercial rights to efti Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet medical need, across all levels of PD-L1 expression (negative, low, and high)SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) — Immutep...